Member Info for CHELSEA7

Can buy just 5k at 7.0936

Can sell now at 6.79 afteran 87.5k sell on NEX

Sell 6.9

Can"t buy 10k

04/08/2020 12:50 138,701 7.2
04/08/2020 12:49 1,583 7

6.70/7.10

+4.55%

6.7/6.933

At 6.94

For another 100k

6.50/7 + 2.27%

50K shares bought at 6.70, showing red as a sell, is a buy!!!

6.30/6.70

6.66 Paid for 30k and another 100k....................more ticks coming!!!

For 100k shares

Buys 213k

Sells 81k

-2.27%

Investment Perspective
Scancell has two promising vaccine platforms, ImmunoBody and Moditope, that have the potential to treat many cancers, either as monotherapy or in combination with checkpoint inhibitors. The leading ImmunoBody programme, SCIB1, is in a combination Phase II study for metastatic melanoma. Moditope is also expected to enter the clinic, with a Modi-1 Phase I/II trial expected to start during 2021. A third platform, AvidiMab, antibodies that target glycans, can be highly specific to tumour cells and has generated significant industry interest. The expertise in inducing potent immune responses is now also being directed towards a potential COVID-19 vaccine. We value Scancell, using a risk adjusted DCF model, at £72.4m, or 15.6p a share.

Douve 15.62p I believe

Bid up to 6.33, Ask up to 6.658

6.649 Paid

6.50 Paid

For 76k

At 6.50............6.20/6.70............Expected IMHO from last night

Morning LL, did you read my post last night from the 22nd July, Results of Placing RNS, also a very good summary there too.

At 6.60.....................I would say a buy